文 | 李典徐梓童大单品驱动收入利润高增，新品布局稳步推进——巨子生物（2367.HK）2024年年报点评事件：公司发布2024年年度报告。点评：24年收入及利润延续高增，销售费用率同比提升3pct24年公司实现营业收入55.39亿元，同比增长57.2%，归母净利润20.62亿元，同比增长42.1%，经调净利润21.52亿元，同比增长46.5%。盈利能力方面，24年毛利率为82.1%，同比-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.